Pan-immune-inflammation in colon cancer:A prognostic biomarker and the role of tumor location in personalized care  

作　　者：Gaya Spolverato Giulia Capelli Floriane Noel Michele Steindler Andrew Alexander Gumbs 

机构地区：[1]Department of Surgery,University of Padova,Padua 35122,Italy [2]Department of Surgery,ASST Bergamo Est,Bergamo 24068,Lombardy,Italy [3]Department of Research,Sibylone,Paris 75002,France [4]Department of Surgery,University of Magdeburg,Magdeburg 39130,Saxony-Anhalt,Germany [5]Department of Surgery,Service de Chirurgie Digestive Minimale Invasive,Hôpital Antoine Béclère,Assistance Publique-Hôpitaux de Paris,Clamart 92140,France

出　　处：《World Journal of Gastrointestinal Surgery》2025年第4期1-6,共6页世界胃肠外科杂志(英文)

摘　　要：Despite advances in surgery,chemotherapy,and radiotherapy,the treatment of colorectal cancer(CRC)requires more personalized approaches based on tumor biology and molecular profiling.While some relevant mutations have been associated with differential response to immunotherapy,such as RAS and BRAF mutations limiting response to anti-epithelial growth factor receptor drugs or microsatellite instability predisposing susceptibility to immune checkpoint inhibitors,the role of inflammation in dictating tumor progression and treatment response is still under investigation.Several inflammatory biomarkers have been identified to guide patient prognosis.These include the neutrophil-lymphocyte ratio,Glasgow prognostic score(GPS)and its modified version,lymphocyte-Creactive protein ratio,and platelet-lymphocyte ratio.However,these markers are not yet included in the standard clinical management of patients with CRC,and further research is needed to evaluate their efficacy in different patient populations.A recent study by Wang et al,published in the World Journal of Gastroenterology,sheds light on the prognostic significance of pan-immune-inflammation value(PIV)in CRC,particularly concerning primary tumor location.Specifically,the authors found that a high PIV was strongly correlated with worse disease-free survival in patients with left-sided colon cancer,whereas no such association was observed in patients with right-sided colon cancer.Integrating tumor location into the prognostic assessment of CRC may improve our ability to more accurately identify high-risk patients and develop personalized treatment plans that are more likely to improve patient outcomes.

关 键 词：Colorectal cancer Inflammatory biomarkers Tumor location Targeted therapy 

分 类 号：R73[医药卫生—肿瘤]